AMGEN INC (AMGN)
AMGEN INC (ticker AMGN) is an independent biotechnology company focused on the discovery, development, and commercialization of therapeutic proteins and biologics. Based in Thousand Oaks, California, the company operates across oncology, cardiovascular disease, inflammation, and immunology, serving millions of patients worldwide through both proprietary medicines and manufacturing partnerships.
What the company does
Amgen discovers and manufactures therapeutic proteins—large-molecule drugs designed to treat serious medical conditions. Unlike traditional small-molecule pharmaceuticals, these biologics are produced through biotechnology processes (often using cell culture or genetic engineering) and require specialized manufacturing, storage, and delivery. The company’s primary therapeutic areas include oncology (cancer treatment), cardiovascular disease prevention and management, bone health, inflammation disorders, and immunology.
The company operates through both internal research and development and through acquisitions. It holds a substantial portfolio of marketed medicines and candidates in clinical development. Amgen’s manufacturing footprint spans multiple continents, reflecting its role as one of the world’s largest biotech manufacturers by scale.
How it makes money
Amgen generates revenue primarily through the sale of proprietary and licensed therapeutic medications. Its income model depends on the continuous cycle of drug development, regulatory approval, market launch, and lifecycle management (including dose optimization and new indication approvals for existing medicines). The company also generates revenue through royalties and milestone payments from collaborative agreements with other pharmaceutical firms.
Unlike many biotech firms, Amgen is profitable and has a mature portfolio of revenue-generating medicines alongside a pipeline of experimental candidates. This combination provides both current cash flow and long-term growth optionality.
Where it sits in its industry
Amgen is one of a small number of fully integrated, independent biopharmaceutical companies—meaning it handles research, manufacturing, and global distribution in-house rather than outsourcing all manufacturing or relying entirely on licensing revenue from partners. It competes with other large integrated biotech firms and multinational pharmaceutical companies that develop biologics.
The company’s scale in manufacturing, regulatory expertise accumulated over decades, and broad therapeutic portfolio position it as a mature leader in the biotechnology sector rather than a pure research-stage biotech. Its size and diversified pipeline also differentiate it from smaller, single-asset biotech companies.
How to research it
Start with Amgen’s 10-K annual report filed with the SEC, which discloses detailed information about its drug portfolio, clinical pipeline, manufacturing capacity, competitive landscape, and regulatory risk factors. The company files quarterly 10-Q reports that provide updates on operational progress, financial results, and pipeline advancement.
Understand the company’s therapeutic focus areas and leading medicines by reviewing its investor relations materials. Track regulatory announcements on new drug approvals or clinical trial results, which significantly influence the company’s long-term value. Patent expiration dates and loss-of-exclusivity schedules for major medicines are material to understanding revenue risk over time.